The DOI matches its Crossref record.
Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?
Open accessAbstract
BACKGROUND: Gonorrhoea has been among the easiest infections to cure with antibiotics. Nevertheless, emerging resistance has driven repeated treatment shifts. Decreased cephalosporin susceptibility is now being reported. We examined cephalosporin MIC trends for Neisseria gonorrhoeae in the UK and undertook pharmacodynamic analyses to predict efficacy against strains with raised MICs. METHODS: Neisseria gonorrhoeae isolates were collected annually in a structured surveillance from 26 genitourinary medicine clinics in England and Wales. MICs were determined by agar dilution and confirmed by Etests. Pharmacodynamic modelling was performed for cefixime and ceftriaxone with Monte Carlo simulations. RESULTS: There was a progressive emergence of small numbers of gonococci with cephalosporin MICs of 0.125-0.25 mg/L; these were not seen before 2005 but, for ceftriaxone and cefixime, respectively, accounted for 0.4% (95% confidence interval 0.2%-1.1%) and 2.8% (1.6%-4.8%) of the 1253 isolates collected in 2008; such MICs are 16-64 times the modal values for the species. Pharmacodynamic analysis was complicated by evidence that cephalosporins need a longer period with the free drug level above MIC than the 7-10 h required for penicillin G; nevertheless, pharmacodynamic analyses predict that failures with the standard 400 mg cefixime po and 250 mg ceftriaxone im regimens become likely around the present MIC maxima. CONCLUSIONS: Gonococci with ceftriaxone and cefixime MICs of 0.125-0.25 mg/L are accumulating in the UK. These MICs lie on the edge of likely responsiveness to current regimens, which need review. Possible responses include: (i) higher cephalosporin doses; (ii) multidose cephalosporin regimens; (iii) multidrug regimens; (iv) microbiologically directed treatment; or, in the future, (v) drug cycling. The practicalities of these approaches are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Sexually Transmitted Infections Treatment Guidelines, 2021
Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A. (2021) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7004a1 · Cited by 3,018
Antimicrobial Resistance in Neisseria gonorrhoeae in the 21st Century: Past, Evolution, and Future
Unemo, M., & Shafer, W. M. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00010-14 · Cited by 1,151
Sexually transmitted infections: challenges ahead
Unemo, M., Bradshaw, C. S., Hocking, J. S., de Vries, H. J. C., Francis, S. C., Mabey, D., Marrazzo, J. M., Sonder, G. J. B., Schwebke, J. R., Hoornenborg, E., et al. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30310-9 · Cited by 751
Ohnishi, M., Golparian, D., Shimuta, K., Saika, T., Hoshina, S., Iwasaku, K., Nakayama, S.-I., Kitawaki, J., & Unemo, M. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00325-11 · Cited by 686
Unemo, M., Golparian, D., Nicholas, R., Ohnishi, M., Gallay, A., & Sednaoui, P. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05760-11 · Cited by 653
2012 European guideline on the diagnosis and treatment of gonorrhoea in adults
Bignell, C., Unemo, M., The European STI Guidelines Editorial Board, Radcliffe, K., Jensen, J. S., Babayan, K., Barton, S., Cusini, M., Gomberg, M., Janier, M., et al. (2013) · International Journal of STD & AIDS · doi:10.1177/0956462412472837 · Cited by 483
Emergence of Multidrug-Resistant, Extensively Drug-Resistant and Untreatable Gonorrhea
Unemo, M., & Nicholas, R. A. (2012) · Future Microbiology · doi:10.2217/fmb.12.117 · Cited by 421
Current Epidemiology and Growing Resistance of Gram-Negative Pathogens
Livermore, D. M. (2012) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2012.27.2.128 · Cited by 417
Self-citationUpdate to CDC's Treatment Guidelines for Gonococcal Infection, 2020
St. Cyr, S., Barbee, L., Workowski, K. A., Bachmann, L. H., Pham, C., Schlanger, K., Torrone, E., Weinstock, H., Kersh, E. N., & Thorpe, P. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6950a6 · Cited by 412
Annual Report of the Chief Medical Officer: infection and the rise of antimicrobial resistance
Davies, S. C., Fowler, T., Watson, J., Livermore, D. M., & Walker, D. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60604-2 · Cited by 393
Self-citationSociety's failure to protect a precious resource: antibiotics
Carlet, J., Collignon, P., Goldmann, D., Goossens, H., Gyssens, I. C., Harbarth, S., Jarlier, V., Levy, S. B., N'Doye, B., Pittet, D., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60401-7 · Cited by 322
Unemo, M., Lahra, M. M., Escher, M., Eremin, S., Cole, M. J., Galarza, P., Ndowa, F., Martin, I., Dillon, J.-A. R., Galas, M., et al. (2021) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00171-3 · Cited by 272
UK national guideline for the management of gonorrhoea in adults, 2011
Bignell, C., FitzGerald, M., & (Guideline Development Group) (2011) · International Journal of STD & AIDS · doi:10.1258/ijsa.2011.011267 · Cited by 270
Unemo, M., Lahra, M. M., Cole, M., Galarza, P., Ndowa, F., Martin, I., Dillon, J.-A. R., Ramon-Pardo, P., Bolan, G., & Wi, T. (2019) · Sexual Health · doi:10.1071/sh19023 · Cited by 262
Lahra, M. M., Martin, I., Demczuk, W., Jennison, A. V., Lee, K.-I., Nakayama, S.-I., Lefebvre, B., Longtin, J., Ward, A., Mulvey, M. R., et al. (2018) · Emerging Infectious Diseases · doi:10.3201/eid2404.171873 · Cited by 239
Metadata
- Authors
- Chisholm, S. A., Mouton, J. W., Lewis, D. A., Nichols, T., Ison, C. A., & Livermore, D. M.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-08-06
- Volume
- 65
- Issue
- 10
- Pages
- 2141-2148
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2098195349
- Cited by
- 174
- References
- 0
- FWCI
- 12.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.